Display options
Cite
Lee JH, Kim HK, Shin BK. Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma. J Pathol Transl Med. 2019;54(1):103-111doi: 10.4132/jptm.2019.10.12.
Lee, J. H., Kim, H. K., & Shin, B. K. (2020). Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma. Journal of pathology and translational medicine, 54(1), 103-111. https://doi.org/10.4132/jptm.2019.10.12
Lee, Jin Hwan, et al. "Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma." Journal of pathology and translational medicine vol. 54,1 (2020): 103-111. doi: https://doi.org/10.4132/jptm.2019.10.12
Lee JH, Kim HK, Shin BK. Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma. J Pathol Transl Med. 2020 Jan;54(1):103-111. doi: 10.4132/jptm.2019.10.12. Epub 2019 Nov 13. PMID: 31718122; PMCID: PMC6986970.
Copy Download .nbib Format: NLM
Share it on

J Pathol Transl Med. 2020 Jan;54(1):103-111. doi: 10.4132/jptm.2019.10.12. Epub 2019 Nov 13.

Expression of female sex hormone receptors and its relation to clinicopathological characteristics and prognosis of lung adenocarcinoma.

Journal of pathology and translational medicine

Jin Hwan Lee, Han Kyeom Kim, Bong Kyung Shin

Affiliations

  1. Department of Pathology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.

PMID: 31718122 PMCID: PMC6986970 DOI: 10.4132/jptm.2019.10.12

Abstract

BACKGROUND: Adenocarcinoma (ADC) of the lung exhibits different clinicopathological characteristics in men and women. Recent studies have suggested that these differences originate from the expression of female sex hormone receptors in tumor cells. The aim of the present study was to evaluate the immunohistochemical expression of female sex hormone receptors in lung ADC and determine the expression patterns in patients with different clinicopathological characteristics.

METHODS: A total of 84 patients with lung ADC who underwent surgical resection and/or core biopsy were recruited for the present study. Immunohistochemical staining was performed for estrogen receptor α (ERα), estrogen receptor β (ERβ), progesterone receptor (PR), epidermal growth factor receptor (EGFR), EGFR E746- A750 del, and EGFR L858R using tissue microarray.

RESULTS: A total of 39 (46.4%) ERα-positive, 71 (84.5%) ERβ-positive, and 46 (54.8%) PR-positive lung ADCs were identified. In addition, there were 81 (96.4%) EGFR-positive, 14 (16.7%) EGFR E746-A750 del-positive, and 34 (40.5%) EGFR L858R-positive cases. The expression of female sex hormone receptors was not significantly different in clinicopathologically different subsets of lung ADC.

CONCLUSIONS: Expression of female sex hormone receptors is not associated with the prognosis and clinicopathological characteristics of patients with lung ADC.

Keywords: Adenocarcinoma of lung; ERα; ERβ; Prognosis; Receptors, estrogen; Receptors, progesterone

References

  1. Cancer Metastasis Rev. 2010 Mar;29(1):37-48 - PubMed
  2. Lung Cancer. 2012 Jun;76(3):280-5 - PubMed
  3. Cancer. 2010 Mar 1;116(5):1234-42 - PubMed
  4. Anticancer Res. 2005 Nov-Dec;25(6C):4693-8 - PubMed
  5. Int J Pediatr. 2009;2009:170491 - PubMed
  6. Biochem Biophys Res Commun. 2001 Jul 13;285(2):340-7 - PubMed
  7. Mod Pathol. 2013 Sep;26(9):1197-203 - PubMed
  8. Int J Cancer. 1996 Jul 29;67(3):357-64 - PubMed
  9. Cancer Res. 1984 Aug;44(8):3448-53 - PubMed
  10. Arch Surg. 1990 Jan;125(1):107-13 - PubMed
  11. Lung Cancer. 2002 Aug;37(2):153-9 - PubMed
  12. Am Rev Respir Dis. 1981 Feb;123(2):205-8 - PubMed
  13. Cancer Sci. 2015 Jan;106(1):51-9 - PubMed
  14. Science. 1995 Dec 1;270(5241):1491-4 - PubMed
  15. Steroids. 2011 Aug;76(9):910-20 - PubMed
  16. Cancers (Basel). 2012 Sep 25;4(4):969-88 - PubMed
  17. J Natl Cancer Inst. 1994 Jun 1;86(11):869-70 - PubMed
  18. Breast Cancer Res Treat. 2012 Nov;136(2):331-45 - PubMed
  19. Clin Cancer Res. 2011 Jan 1;17(1):154-64 - PubMed
  20. Horm Cancer. 2018 Aug;9(4):288-294 - PubMed
  21. Cancer Res. 1985 Sep;45(9):4206-14 - PubMed
  22. Oncol Rep. 2010 Nov;24(5):1331-8 - PubMed
  23. Oncotarget. 2015 Sep 29;6(29):27505-18 - PubMed
  24. Cell Mol Life Sci. 2009 Dec;66(24):3873-94 - PubMed
  25. APMIS. 2012 Jun;120(6):451-8 - PubMed
  26. Clin Cancer Res. 2009 Sep 1;15(17):5359-68 - PubMed
  27. Lung Cancer. 2008 Jan;59(1):88-94 - PubMed
  28. Onco Targets Ther. 2015 Oct 09;8:2849-63 - PubMed
  29. Hum Pathol. 2010 Feb;41(2):190-8 - PubMed
  30. Mol Cell Biol. 2003 Dec;23(23):8542-52 - PubMed
  31. Cancer. 2008 Sep 1;113(5):1012-8 - PubMed
  32. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  33. Arch Pathol Lab Med. 2000 Oct;124(10):1467-70 - PubMed
  34. Ann Thorac Surg. 2011 May;91(5):1562-7 - PubMed
  35. J Clin Oncol. 2009 Jan 20;27(3):411-7 - PubMed
  36. Oncotarget. 2016 Dec 13;7(50):82648-82657 - PubMed
  37. Cancer Res. 1982 Aug;42(8):3232-9 - PubMed
  38. Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 - PubMed
  39. J Thorac Oncol. 2010 Jan;5(1):17-22 - PubMed
  40. Oncol Lett. 2014 Dec;8(6):2379-2386 - PubMed
  41. Clin Cancer Res. 2005 Oct 15;11(20):7280-7 - PubMed

Publication Types